Physician profile
David Neuman
NPI 1407896350
$971.62
in general payments reported to CMS, 2019-2025
20 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $93.96 · 2021: $116 · 2022: $108 · 2023: $158 · 2024: $13.20 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $178.93 | 2019-2023 | Andexxa |
| Novo Nordisk INC | $125.11 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $117.97 | 2019-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $90.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $62.08 | 2019-2021 | |
| Lilly USA, LLC | $47.98 | 2019-2023 | Mounjaro |
| Pfizer INC. | $44.34 | 2019-2021 | |
| Astellas Pharma US INC | $39.60 | 2019 | |
| Dexcom, INC. | $39.08 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.43 | 2020 | |
| Philips North America LLC | $32.67 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Amgen INC. | $22.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.30 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.24 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $16.71 | 2020 | |
| Glaxosmithkline, LLC. | $16.48 | 2025 | Arexvy, Shingrix |
| Cardiovascular Systems INC. | $15.41 | 2019 | |
| Abbvie INC. | $14.11 | 2023 | |
| Merck Sharp & Dohme LLC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Neuman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.